Aat033 News Today

Data, which were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2022, includes results of 81 patients with gastrointestinal acute Graft-versus-Host Disease

MaaT Pharma received authorizations from French and German regulatory authorities to initiate its Phase 2b clinical trial evaluating MaaT033 in improving survival in patients receiving allogeneic

Data describe rapid, safe and robust microbiome engraftment1 of MaaT033 in the gut of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome undergoing intensive chemotherapy